12,372 trials
Moderate and Severe Active Rheumatoid Arthritis · Active Psoriatic Arthritis · Active Ankylosing Spondylitis
Primary: Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 — 100.00; 96.88 percentage of subjects
Breast Cancer
Primary: Number of Participants With Disease-free Survival (DFS) Event — 127; 170 Participants
Arthritis, Rheumatoid
Primary: Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) After the Second Infusion of the First Dose — 149398; 172463; 158529 h*µg/mL
Diphtheria-Tetanus-acellular Pertussis Vaccines
Primary: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D). — 437; 1 Participants
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 336; 334; 29; 31 Participants
Charcot Joint of Foot
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 7 Participants
Hyperemia
Primary: Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale — 1.82; 1.71; 0.58; 1.40 units on a scale
Community Acquired Pneumonia
Primary: Early Clinical Response (ECR) — 241; 248; 29; 21 Participants
Diarrhea
Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score — -0.38; -1.25 score on a scale — p=<0.0001
Hyperemia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 66; 38; 44; 25 Participants
Onychomycosis
Primary: Primary Endpoint - Efficacy — 4 Participants
Colorectal Cancer Metastatic
Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43
Lung Cancer
Primary: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population — 9.56; 9.17 Months — p=0.3693
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 42.9; 75.5; 83.7; 80.0 percentage of participants — p=<0.001